EMAPALUMAB IN TREATMENT-EXPERIENCED PRIMARY HLH: SAFETY, EFFICACY, AND TRANSPLANT OUTCOMES FROM THE OPEN-LABEL, SINGLE-ARM POST-AUTHORIZATION STUDY SOBI.EMAPALUMAB-104 IN CHINESE PATIENTS
EHA Library, Rui Zhang,
4210550
CHRONIC KIDNEY DISEASE PREDICTS DELAYED PLATELET ENGRAFTMENT, INCREASED TRANSFUSION REQUIREMENTS, AND HIGHER INFECTIOUS MORBIDITY FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION
EHA Library, Anamarija Vrkljan Vuk,
4210570
DEEP 52-PARAMETER FLOW CYTOMETRY REVEALS PROFOUND PERIPHERAL T-CELL SENESCENCE, EXHAUSTION, AND DISTINCT MICROENVIRONMENTAL SIGNATURES IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS
EHA Library, Yajing Zhang,
4210500
COMPREHENSIVE GENOMIC PROFILING OF LYMPHOID MALIGNANCIES USING TARGETED PANELS IN A SOUTH ASIAN–ENRICHED INTERNATIONAL COHORT: MUTATIONAL LANDSCAPE, CLONAL ARCHITECTURE, AND THERAPEUTIC ACTIONABILITY
EHA Library, Rahul Bhargav,
4210507
HIGH-DOSE MELPHALAN FOLLOWED BY DONOR STEM CELL INFUSION AS SALVAGE THERAPY FOR RELAPSED/REFRACTORY ACUTE LEUKEMIA AFTER ALLO-HSCT: A MULTICENTER, SINGLE-ARM, RETROSPECTIVE STUDY
EHA Library, MINGLU LI,
4210559
ALEMTUZUMAB AS A SUBSTITUTE FOR ATG IN THE FBM (FLUDARABINE, BCNU, MELPHALAN) CONDITIONING REGIMEN: COMPARABLE OUTCOMES IN PATIENTS WITH HIGH HCT-CI AND AGE > 60, BUT INFERIOR OUTCOMES IN AML
EHA Library, Andreas Guenther,
4210592